CD8A and lung carcinoma: Numerous other nanomedicine, including Nanomedicine SGT-53 and AZD1080, have demonstrated their ability to overcome immunotherapy resistance by enhancing tumor immunogenicity and promoting the release of CD8+ T cells, thus overcoming lung cancer resistance to ICB[149].